H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on TGTX stock, giving a Buy rating on June 21.

4th of July Sale - 70% Off

• Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
• Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Emily Bodnar has given his Buy rating due to a combination of factors, including TG Therapeutics’ strategic move to explore Briumvi in treatment-resistant schizophrenia while maintaining its core multiple sclerosis franchise. The new Phase 2 study represents a relatively low-cost way to test B-cell depletion in a high-need psychiatric indication, offering meaningful upside without being required to support the current valuation.

She notes that prior proof-of-concept data with rituximab in schizophrenia spectrum disorders provide a mechanistic and clinical rationale, and Briumvi’s more complete and rapid B-cell depletion could translate into improved and more durable patient outcomes. At the same time, her financial model and $70 price target do not assume any contribution from the schizophrenia program, so positive signals from this trial would add incremental value rather than being needed to justify the Buy rating, keeping the risk/reward profile attractive for investors.

In another report released on June 21, Jefferies also assigned a Buy rating to the stock with a $83.00 price target.